Timing of Eating Study Among Obese Adults

Sponsor
University of Pennsylvania (Other)
Overall Status
Recruiting
CT.gov ID
NCT03354169
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
80
1
2
61.7
1.3

Study Details

Study Description

Brief Summary

The randomized, cross-over design study is designed to determine how timing of eating affects weight, adiposity, energy metabolism, and gene expression. Obese participants will be provided isocaloric meals and snacks to be consumed in one of two prescribed eating conditions -- daytime eating and delayed eating.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Eating Condition
N/A

Detailed Description

The study consists of the following phases - screening, assessment visit 1, eating condition 1, assessment visit 2, a wash-out period, assessment visit 3, eating condition 2 and assessment visit 4, as discussed in detail below. The assessment visits will all consist of the same procedures and will take place at the Center for Human Phenomic Science (CHPS) of the Hospital of the University of Pennsylvania before and after each of the eating conditions (four times total). The four 28-hour inpatient assessments will consist of blood draws, adipose (fat) tissue sampling, a dual energy X-ray absorptiometry (DEXA) scan, and a resting metabolic rate test.

During the screening period in order to determine eligibility, participants must complete a 2-part screening visit; This includes:

  1. A complete physical examination

  2. Tests of blood to screen for any conditions such as diabetes or any serious, uncontrolled medical condition that may interfere with participation in the study.

  3. An Electrocardiogram (EKG) test

  4. Urine Pregnancy Test

  5. Urine Drug Screening

  6. the completion of several self-report questionnaires and structured interviews

During the screening period, participants will also be asked to keep a 10-day food log where they will record all food and beverages consumed and their sleep and exercise schedule. Participants will be asked to wear an Actigraph wrist watch at this time.

Following successful completion of the screening period, participants will complete the first of 4 assessment visits. All assessment visits will follow the same protocol.

Assessment Visit Day 1 Procedures:

The visit will include 28 hours (overnight) spent at the CHPS, where meals and snacks will be provided. At each of the assessment visits participants will be given a urine drug screening and, if appropriate, a pregnancy test. The lights will be dim in the hospital room to control for light.

Participants will arrive at 7:00 am. Starting at 8:00 am, blood will be drawn every four hours. From this blood gene expression and hormones related to metabolism, eating, and sleep will be measured.

Following the first blood draw, resting metabolic rate is measured for 45 minutes. Lunch is then provided, followed by a measurement of body composition using a DEXA scan. Next, the adipose tissue sampling procedure will begin. Lastly, the participants will complete a series of cognitive tests administered on a laptop.

Participants will be provided meals and snacks during their visit and are free to watch television or participate in other sedentary pastimes while they are there.

Assessment Visit Day 2 Procedures:

After an overnight fast, participants will undergo the Frequently Sampled Intravenous Glucose Tolerance Test (FSIGT) on the morning of day 2.

Following the FSIGT test, participants will be served a meal and during the first assessment visit, participants will be randomly assigned to start with one of two eating conditions for the next 8 weeks: 1) Daytime or 2) Delayed. Following randomization, participants will be discharged from CHPS and begin eating condition 1.

If participants are assigned to the daytime eating condition first, they will be asked to consume all of their meals and snacks each day between 8:00 am and 7:00 pm. If they are assigned to the delayed eating condition first, they will be asked to consume all of their meals and snacks between 12 noon and 11:00 pm each day. Participants will eat on this schedule for 8 weeks. During the two, 8-week eating periods, all of the meals and snacks will be provided by the research kitchen. During the eating conditions, participants will be asked to complete daily self-report queries concerning their adherence to the food, sleep, and physical activity requirements of the study.

Following eating condition 1, participants will return for assessment visit 2. This assessment visit follows the same procedures as all other assessment visits. Following assessment visit 2, participants will begin their 2 week washout period where they are instructed to eat as they normally would whenever they like. Following the two-week washout period, participants will return for assessment visit 3, after which they will begin eating condition 2. Following 8 weeks of eating condition 2 participants will return for their final visit, assessment visit 4. After this final assessment, participation in the study will be complete.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomized within subjects, cross-over designRandomized within subjects, cross-over design
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Daytime vs. Delayed Eating Among Obese Adults
Actual Study Start Date :
Feb 7, 2018
Anticipated Primary Completion Date :
Mar 31, 2023
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Daytime Eating Condition

Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.

Behavioral: Eating Condition
Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.

Experimental: Delayed Eating Condition

Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.

Behavioral: Eating Condition
Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.

Outcome Measures

Primary Outcome Measures

  1. body mass (weight) [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    changes in body mass, as measured by a calibrated digital scale, will be explored.

  2. adiposity [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    changes in measures of body fat, as measured by a DEXA scan, will be explored.

  3. energy homeostasis outcomes [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    Changes in resting energy expenditure values will be explored.

Secondary Outcome Measures

  1. circadian ghrelin rhythms [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    differences in circadian ghrelin rhythms will be explored.

  2. circadian leptin rhythms [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    differences in circadian leptin rhythms will be explored.

  3. gene expression profiles [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    differences in the phase and cycling of gene expression profiles will be explored.

  4. insulin sensitivity [pre-post changes between the daytime and delayed eating conditions (8 weeks).]

    changes in insulin sensitivity will be explored.

  5. free fatty acid dynamics [pre-post changes between the daytime and delayed eating conditions (8 weeks)]

    changes in free fatty acid dynamics will be explored.

  6. adipose tissue gene expression [pre-post changes between the daytime and delayed eating conditions (8 weeks)]

    changes in adipose tissue gene expression will be explored.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • age 21-50

  • BMI of 30-50 kg/m2

  • stable weight (±10 lb) over the previous 6 months

  • women must be pre-menopausal with regular menstrual cycles

Exclusion Criteria:
  • unstable, serious medical conditions

  • use of medicine linked to weight gain/loss

  • cardiac conditions

  • cancer

  • diabetes

  • autoimmune disease

  • use of illicit drugs, melatonin, diuretics or hypnotics

  • involved in a current weight loss program

  • presence of an untreated sleep disorder (determined by surveys and actigraphy)

  • those who work shift work

  • those with extreme chronotypes

  • habitual waking outside of 0600h-0930h

  • habitual bedtime <2200h or >2400h

  • sleep duration of <6.5 or >8.5 h/night.

  • psychiatric exclusions will be: depression (Patient Health Questionnaire-9 score ≥9), lifetime bipolar disorder, psychosis, or eating disorder; or any other severe psychiatric disorder judged to interfere with study adherence as assessed by the MINI International Neuropsychiatric Interview.

  • structured exercise >3 d/wk, for >30 min measured by exercise logs and actigraphy; normal activity levels are required during the study (±30 min/wk of baseline level).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Weight and Eating Disorders, Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • University of Pennsylvania
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kelly Allison, Director, Center for Weight and Eating Disorders, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT03354169
Other Study ID Numbers:
  • 828317
  • R01DK117488-01
First Posted:
Nov 27, 2017
Last Update Posted:
Jul 28, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kelly Allison, Director, Center for Weight and Eating Disorders, University of Pennsylvania

Study Results

No Results Posted as of Jul 28, 2022